**Summary**
Genflow Biosciences Plc, a UK-based biotechnology company focused on gene therapies for age-related diseases, announced the administrative approval of €4 million in non-dilutive funding from the Wallonia Region of Belgium. This funding, expected to be disbursed by May 2026, will support the development of their lead gene therapy candidate, GF-1002, for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company outlined its 2026 priorities, emphasizing pipeline discipline, capital efficiency, and securing early-stage collaborations for non-dilutive funding and external validation. Key programs include
1. **GF-1004 Dog Aging Study**A blinded clinical trial assessing benefits related to sarcopenia, healthspan, and lifespan biomarkers, with initial efficacy readouts expected in Q1 2026 and further results in June-July 2026.
2. **Glaucoma Program**Focused on delivery optimization and execution readiness, including partnerships for lipid nanoparticle (LNP) innovation and RNA-based formulation activities.
3. **Sarcopenia Program**Advancing in line with established development plans.
4. **ExoFastTrack Initiative**Generating data to support and accelerate multiple pipeline programs.
CEO Dr. Eric Leire highlighted the funding as reinforcing Genflow’s ability to execute its 2026 priorities with discipline, focusing on programs with clear execution paths, strong scientific rationale, and partnership opportunities. The company remains committed to scientific rigor, operational execution, and long-term shareholder value creation.